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Purpose: p-Synephrine, the principal alkaloid of bitter orange (Citrus aurantium), is 20 
widely used in dietary supplements for weight loss due to its purported effect of 21 
increasing fat oxidation.  However, there is a paucity of scientific information about its 22 
effectiveness in enhancing fat oxidation during exercise. The aim of this investigation 23 
was to determine the effect of an acute dose of p-synephrine on substrate oxidation during 24 
prolonged and constant intensity exercise. Methods:  In a double-blind and randomized 25 
experiment, 14 healthy subjects performed two acute experimental trials after ingesting 26 
either p-synephrine (3 mg·kg-1) or a placebo (cellulose).  Energy expenditure and fat 27 
oxidation rates were continuously measured by indirect calorimetry during 1 h of 28 
continuous cycling at Fatmax, the intensity that induces maximal fat oxidation rate. 29 
Results:  In comparison to the placebo, energy expenditure during 1 h of cycling 30 
remained unchanged with p-synephrine (698±129 vs. 686±123 kcal, P=0.08).  However, 31 
p-synephrine increased whole-body fat oxidation (33.6±10.4 vs. 37.3±9.8 g, P<0.01) 32 
while also reducing carbohydrate oxidation (99.5±30.4 vs. 85.0±28.4 g, P<0.01).  33 
However, the magnitude of the shift on substrate oxidation induced by p-synephrine was 34 
small.  Conclusion: Acute ingestion of p-synephrine augments fat oxidation during 35 
prolonged and constant-intensity exercise.  36 
Keywords:  nutrition supplement; exercise; citrus aurantium; bitter orange; maximal fat 37 
oxidation. 38 




Several forms of exercise have been deemed as effective in inducing a permanent 41 
loss of body mass and a reduction in body adiposity [1].  However, exercise volume, 42 
frequency and intensity are key factors for the efficacy of exercise training in the 43 
prevention of weight gain, for weight loss, and for prevention of weight regain after 44 
weight loss [2].  While diet is a potent and operative strategy to reduce body mass and 45 
body fat, the addition of exercise to a diet increases the cardiovascular, metabolic, and 46 
body composition benefits of a weight loss program [3].  Dietary supplements are also 47 
used alone or in combination with exercise and diet to produce more effective body 48 
composition changes, but scientific literature that demonstrates the efficacy of most 49 
commercially-available dietary weight loss supplements is scarce. Overall, dietary 50 
supplements for weight management seek to increase energy expenditure and/or enhance 51 
fat oxidation at rest or during exercise [4].  While many botanical and other types of 52 
dietary supplements are sold under the premise of  increasing energy expenditure or fat 53 
utilization, only caffeine has been systematically found as effective in increasing fat 54 
oxidation at rest [5] and during exercise [6].   55 
p-synephrine, the most active substance in citrus aurantium, is a substance widely 56 
included in dietary supplements for weight loss [7]. It is often included in dietary 57 
supplements as a way to purportedly increase fat oxidation within the body. Its presence 58 
in the supplement market rose after the Food and Drug Administration (FDA) issued a 59 
final rule prohibiting the sale of dietary supplements containing ephedrine alkaloids in 60 
2004.  Concerns about the safety of p-synephrine were initially raised [8] but several most 61 
recent investigations have provided scientific evidence regarding the lack of acute and 62 
long-term side effects derived from p-synephrine intake [9]. Nevertheless, the 63 
effectiveness of p-synephrine at enhancing fat oxidation has only been found in a few 64 
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investigations [6, 10, 11].  In these investigations, p-synephrine (at a dose of 2-3 mg·kg-65 
1) enhanced whole-body fat oxidation at low-to-moderate exercise intensity, while this 66 
change in substrate oxidation was identified by using a short-time exercise protocol of 67 
increasing intensity that allows the assessment of fat oxidation rates at several exercise 68 
intensities in only one experimental session.  However, this ramp exercise test used in 69 
previous research has little applicability to exercise training for weight loss because the 70 
duration (12-21 min) impedes high values of energy expenditure or fat oxidized.  To the 71 
date, there is no investigation that have studied the effect of p-synephrine during 72 
prolonged continuous exercise, despite this training routine is typically used in weight 73 
loss programs [1]. 74 
Due to the current body of scientific evidence, it is difficult to ascertain whether 75 
p-synephrine is an effective substance to increase the amount of fat utilized during an 76 
exercise training session.  For this reason, the aim of this research was to determine the 77 
effect of an acute ingestion of p-synephrine on substrate oxidation during 1 h of steady-78 
state cycling at the intensity of maximal fat oxidation.   79 
 80 
METHODS 81 
Subjects. Fourteen young and healthy participants volunteered to participate in 82 
this investigation (age= 31±6.9 years, body mass= 71.0±5.8 kg, height= 1.76±0.04 m, 83 
body mass index= 22.7±1.8 kg·m2, maximal oxygen uptake [VO2max] = 56.7±10.6 mL·kg
-84 
1·min-1).  There were two women in the sample that performed all the experimental trials 85 
in their luteal phase.  One week before the study’s onset, participants were fully informed 86 
of the experimental standards and risks associated with the research. Participants signed 87 
an informed written consent form to participate in the investigation.  The study was 88 
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approved by the Camilo José Cela University Research Ethics Committee, in accordance 89 
with the Declaration of Helsinki. 90 
Experimental design.  A double-blind, placebo-controlled, and randomized 91 
experimental design was used in this investigation. Each participant took part in 2 92 
experimental trials separated by 3 days to allow for complete recovery and substances 93 
elimination.  Participants either ingested 3 mg of p-synephrine per kg of body mass (99% 94 
purity; Synephrine HCL, Nutrition Power, Spain) that was contained in an opaque capsule 95 
or an identical capsule filled with a placebo (100% cellulose, Guinama, Spain).  The 96 
capsules were ingested with 150 mL of tap water 60 min before the onset of the 97 
experimental trials. An alphanumeric code was assigned to each trial by a person 98 
independent of the study in order to blind the participants and investigators to the tested 99 
substances.  Environmental temperature and humidity (mean ± standard deviation was 100 
21.2±0.4 ºC for air temperature and 43±9% for relative humidity) were recorded using a 101 
digital temperature and humidity monitor (OH1001, OH Haus, Spain). 102 
Pre-experimental procedure.  One week before the first experimental trial, 103 
participants underwent standardized warm-up that included 10 min at 50 W on a cycle 104 
ergometer (SNT Medical, Cardgirus, Spain).  They then completed a ramp exercise test 105 
on the cycle ergometer, which was comprised of 25 W increments every 3 minutes until 106 
volitional fatigue.  During the test, participants chose a cadence between 70 and 90 rpm 107 
and the test was finished when participants were unable to maintain a cadence > 50 rpm.  108 
During the incremental exercise test, oxygen uptake (VO2) and carbon dioxide production 109 
(VCO2) were measured through indirect calorimetry.  Participants were continuously 110 
measured by a breath-by-breath analyzer (Metalyzer 3B, Cortex, Germany) to calculate 111 
fat oxidation and carbohydrate oxidation rates at each stage.  The exercise intensity in 112 
which the maximal rate of fat oxidation was achieved (Fatmax; mean ± standard deviation 113 
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was 147 ± 39 W) was registered and used for the subsequent experimental trials. The 114 
ramp exercise test was considered maximal and valid when the end criteria for VO2max 115 
were reached at the end of the test: VO2 stabilization despite increases in ergometric 116 
power, the respiratory exchange ratio was higher than 1.10, the participant’s rating of 117 
perceived exertion -- measured with the 6-to-20-point Borg scale-- was higher than 19 118 
points while participants’ heart rate was superior to 80% of the age-adjusted estimate of 119 
maximal heart rate [12]. On the subsequent day, a familiarization protocol as described 120 
below was performed on all individuals.  121 
Experimental procedures. Twenty-four hours before each experimental trial, 122 
participants refrained from strenuous exercise and adopted a similar diet and fluid intake 123 
regimen. Subjects were also required to refrain from consuming alcohol, caffeine, and 124 
foods that contained citrus aurantium (e.g., bitter orange, sweet orange and tangerine) for 125 
24 h before each trial.  To standardize these routines, subjects were requested to complete 126 
a 24-h dietary record on the day before the first trial and to follow the same dietary pattern 127 
before the second visit. On the day of the experimental trials, participants arrived at the 128 
laboratory (09.00 am) in a fasted state (at least 8 hours after their last meal).  Upon arrival, 129 
the capsule with the assigned experimental treatment was provided in an unidentifiable 130 
bag and then later ingested by the participant.  Then, participants rested supine for 60 min 131 
to allow for substance absorption. Resting heart rate and systolic and diastolic blood 132 
pressure (M6 Comfort, Omron, Japan; by triplicate) were measured during the last 5 min 133 
of the resting period. An average of three blood pressure measurements was used for 134 
analysis. 135 
After the resting measurements, participants performed a standardized warm-up that 136 
included 10 min on the same cycle ergometer used for the ramp test.  During the warm-137 
up, exercise intensity was progressively increased until reaching individual Fatmax as 138 
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measured in the pre-experimental trial (equivalent to 57.1±6.4% of VO2max). At the end 139 
of the warm-up, participants completed 1 h of constant exercise at Fatmax.  During the 140 
whole trial, heart rate (Wearlink, Polar, Finland) and gas exchange data were obtained – 141 
as previously described for the incremental exercise test – and averaged every 5 minutes 142 
in order to achieve a representative value.  In the first experimental trial, pedaling cadence 143 
was freely chosen between 70 and 90 rpm, but it was recorded at 5 min intervals and 144 
replicated in the second trial.  An average for the rate of substrate oxidation was calculated 145 
in these 5-min periods and the amount of fat and carbohydrate oxidized were also 146 
calculated for the whole trial.  The same procedures were used for the two experimental 147 
trials.   148 
Statistical Analysis. The results of each test were blindly introduced into the 149 
statistical package SPSS v 20.0 and analyzed afterwards. The normality of each 150 
quantitative variable was initially tested with the Shapiro-Wilk test.  All the quantitative 151 
variables included in this investigation presented a normal distribution and parametric 152 
statistics were used to determine differences among trials. A one-way analysis of variance 153 
(ANOVA) was used to compare heart rate and blood pressure at rest.  A two-way 154 
ANOVA (treatment × time) was used to compare the variables obtained during exercise.  155 
After a significant F test (Geisser–Greenhouse correction for the assumption of 156 
sphericity), differences between means were identified using Tukey’s post- hoc tests.  157 
Only the main effects for substance are presented for clarity.  Paired t-tests were used to 158 
compare total energy expenditure and total fat and carbohydrate oxidation in the p-159 
synephrine and placebo trials.  The significance level was set at P < 0.05.  The data are 160 
presented as mean±standard deviation.  The effect size (±90% confidence intervals (CI)) 161 




RESULTS  164 
In comparison to the placebo, the ingestion of p-synephrine did not modify resting 165 
heart rate nor systolic, diastolic, and mean arterial blood pressure (Table 1). During 166 
exercise, there was no main effect of p-synephrine on heart rate (P = 0.13) and exercise 167 
heart rate was unaffected by the ingestion of p-synephrine at any time point. Similarly, 168 
there was no main effect of p-synephrine on the rate of energy expenditure (P = 0.11) and 169 
the rate of energy expenditure was unaffected by the ingestion of p-synephrine at any 170 
time point during 1-h exercise trial.  The total energy expended during the trial was very 171 
comparable between substances (Table 1).   172 
There was a main effect of p-synephrine on fat oxidation rate (P < 0.01) while the 173 
pairwise comparison indicated that fat oxidation was higher with p-synephrine than with 174 
placebo from min-25 to min-60 of the 1-h cycling trial (all P < 0.05, likely-most likely, 175 
Figure 1). As a result, total fat oxidation was higher with p-synephrine than with placebo 176 
(Table 1).  There was a main effect of p-synephrine on carbohydrate oxidation rate (P < 177 
0.01) and the pairwise comparison indicated that p-synephrine reduced carbohydrate 178 
utilization at min-5, min-20, and from min-30 to the end of the 1-h cycling trial (all P < 179 
0.05, likely-most likely, Figure 1).  As a result, total carbohydrate oxidation was reduced 180 
in comparison the placebo (Table 1).  Figure 2 depicts the individual responses to p-181 
synephrine ingestion on substrate oxidation during exercise. Out of the 14 participants, 182 
11 (79%) presented a lower amount of carbohydrate oxidized with p-synephrine while 12 183 
participants (86%) increased the amount of fat oxidized during the 1-h cycling trial with 184 
p-synephrine.   185 
 186 
DISCUSSION 187 
This investigation is novel because it is the first experiment that assesses the effect 188 
of acute p-synephrine intake on fat oxidation during a protocol of continuous exercise 189 
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that simulates an exercise session.  This investigation is also valuable because this 190 
substance is commonly included in dietary supplements to reduce body fat and body mass 191 
without a proper scientific background to support its effectiveness [7].  The main results 192 
of this investigation suggest that 3 mg·kg-1 of p-synephrine might increase the amount of 193 
fat oxidized by 11.1±10.5% in 1 h of exercise at Fatmax, without affecting total energy 194 
expenditure or exercise heart rate. p-Synephrine was also accompanied by a reduction of 195 
carbohydrate utilization by 13.5±13.3%.  Taken together, acute p-synephrine intake might 196 
be effective at producing a moderate shift towards enhanced utilization of fat during 197 
continuous steady-state exercise.  198 
In animal models, it has been found that p-synephrine can bind to β‐3 adrenergic 199 
receptors, resulting in enhanced lipid metabolism [7, 13].  Although the evidence is still 200 
scarce, a few investigations in humans have found that p-synephrine can potentially 201 
induce changes in substrate oxidation at rest and during exercise [6, 10, 11, 14].  To this 202 
regard, it has been suggested that activation of β-3 adrenoreceptors by p-synephrine might 203 
be responsible for the enhanced fat oxidation found in humans [15] although this 204 
hypothesis still requires confirmation.  Due to the structural similarities of p-synephrine 205 
to that of epinephrine and nor-epinephrine, concerns have been raised regarding this 206 
substance’s safety [8].  However, the binding of p-synephrine to α-, β-1 and β-2 207 
adrenergic receptors is low, which explains its non-effect in causing cardiovascular 208 
effects -- even after 15 days of continuous ingestion [13].  This selective affinity of p-209 
synephrine to adrenergic receptors means that this substance has a comparable effect to 210 
caffeine in increasing fat oxidation during exercise, but without the caffeine-induced 211 
effects on blood pressure [6].  These evidences for efficacy and safety of p-synephrine 212 
support the use of this substance for weight management although additional human 213 
studies are required to determine long-term safety and efficacy.   214 
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Although the acute pre-exercise intake of p-synephrine significantly increased the 215 
amount of oxidized fat during 1 h of cycling, its effect was small.  In absolute terms, p-216 
synephrine augmented the utilization of fat by 3.7±3.3 g·h-1 -- equivalent to 0.06 g·min-1 217 
for the duration of the trial.  The increase in fat oxidation induced by p-synephrine in the 218 
current investigation was slightly inferior to the ones found during exercise of increasing 219 
intensity (from 0.11 to 0.20 g·min-1) with the same dose [10, 11].  The difference among 220 
investigations might be related to the different of tests used (constant cycling at Fatmax 221 
vs increasing exercise intensity cycling test).  In any case, this and previous investigations 222 
suggest the usefulness of p-synephrine in increasing the usage of fat during aerobic 223 
exercise. Interestingly, in all these investigations, the effect of p-synephrine on substrate 224 
oxidation was never accompanied by any change on energy expenditure. This also 225 
suggests that this substance cannot be considered as thermogenic.   226 
In summary, pre-exercise ingestion of 3 mg of p-synephrine per kg of body mass 227 
was effective at producing a shift on substrate oxidation during 1 h of continuous cycling 228 
at Fatmax. With the ingestion of this protoalkaloid, the utilization of fat was enhanced at 229 
the expense of carbohydrate oxidation.  This investigation is a step forward at confirming 230 
the efficacy of p-synephrine in modulating substrate utilization during exercise -- 231 
although this effect is of a small magnitude.  Nevertheless, further experiments are needed 232 
to ascertain tolerance to this substance and its real contribution at enhancing reductions 233 
in body fat during weight loss programs.  Lastly, the outcomes found in this investigation 234 
are not transferable to bitter orange or citrus aurantium dietary supplements because these 235 
natural compounds contain more substances than p-synephrine and the concentrations of 236 
this alkaloid are typically lower than the one used in the current investigation.  237 
 238 
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Table 1. Metabolic and cardiovascular responses at rest and during 1 h of cycling at Fatmax after the ingestion of p-synephrine or a placebo.  
Data is shown as mean±SD for 13 healthy participants.   
  
Variables (Units) Placebo p-Synephrine 
Effect size 
(±90% CI) 
Qualitative inference P value 
Resting heart rate (beats/min) 50±8 50±8 0.0 (-0.3 / 0.3) Unclear 0.84 
Resting systolic blood pressure (mmHg) 118±8 118±7 0.0 (-0.3 / 0.2) Unclear 0.80 
Resting Diastolic blood pressure (mmHg) 70±8 68±8 -0.2 (-0.5 / 0.1) Possible 0.19 
Mean arterial blood pressure (mmHg) 86±7 85±6 -0.2 (-0.4 / 0.1) Possible 0.29 
Total fat oxidation (g) 33.6±10.4 37.3±9.8 0.3 (0.2 / 0.5) Likely <0.01 
Total carbohydrate oxidation (g) 99.5±30.4 85.0±28.4 -0.5 (-0.7 / -0.2) Likely <0.01 
Total energy expenditure (kcal) 698±129 686±123 -0.2 (-0.3 / 0.1) Most unlikely 0.08 
Average heart rate (beats/min) 127±12 126±12 0.1 ( -0.2 / 0.4) Unclear 0.63 







Figure 1. Carbohydrate (upper panel) and fat (lower panel) oxidation rates during 1 h of 
cycling at Fatmax after the ingestion of p-synephrine or a placebo.  
(*) p-Synephrine different from placebo at P < 0.05. 
 
 
Figure 2. Individual responses for carbohydrate (upper panel) and fat (lower panel) 
oxidation rates during 1 h of cycling at Fatmax after the ingestion of p-synephrine or a 
placebo.   
 
(*) p-Synephrine different from placebo at P < 0.05. 
 
